TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27121224

Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback
Number of subjects: 75

Group type: COMPARATOR
Intervention: Mental imagery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 75
Study: 24375756

Group type: EXPERIMENTAL
Intervention: High-fluoride toothpaste (5000 ppm fluoride)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Regular toothpaste (1450 ppm fluoride)
Number of subjects: 424
Study: 21482119

Group type: EXPERIMENTAL
Intervention: Two anterolateral lag screws
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anteromedial Limited Contact Dynamic Compression Plate (LC‐DCP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral locking plate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Posterolateral buttress plate
Number of subjects: 40
Study: 19068191

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 1480

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Deferiprone
Number of subjects: 1480

Group type: COMPARATOR
Intervention: DFO
Number of subjects: 1480
Study: 17335365

Group type: EXPERIMENTAL
Intervention: Subgingival chlorhexidine varnish administration
Number of subjects: 33

Group type: COMPARATOR
Intervention: Same-day full-mouth root planing
Number of subjects: 33
Study: 15252293

Group type: EXPERIMENTAL
Intervention: Sertraline (200 mg/day) for 14 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11483123

Group type: EXPERIMENTAL
Intervention: Extended interventions (mail only, infrequent telephone and mail, or frequent telephone and mail)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Computer and provider counseling components (no further contact)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Targeting a behavior
Number of subjects: 117
Study: 10201553

Group type: EXPERIMENTAL
Intervention: 7.0 g ispaghula/day
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: 10.5 g ispaghula/day
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Ispaghula and modification of diet
Number of subjects: 340
Study: 7822917

Group type: EXPERIMENTAL
Intervention: Compression glove and early mobilization
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plaster splint
Number of subjects: 42
Study: 3243671

Group type: EXPERIMENTAL
Intervention: Internal visualization (imaging with eyes closed)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 31241036

Group type: EXPERIMENTAL
Intervention: Structured peer-led diabetes self-management and support
Number of subjects: 0
Study: 28468518

Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Number of subjects: 63

Group type: COMPARATOR
Intervention: oral morphine
Number of subjects: 63
Study: 25041464

Group type: EXPERIMENTAL
Intervention: Social Desirability Scale‐17
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: School education
Number of subjects: 1243
Study: 23331802

Group type: EXPERIMENTAL
Intervention: Probiotics administered to 32 patients for 3 months post-pullthrough
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo administered for 3 months post-pullthrough
Number of subjects: 62
Study: 21418830

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 320
Study: 19748859

Group type: EXPERIMENTAL
Intervention: Echinacea/sage spray
Number of subjects: 154

Group type: COMPARATOR
Intervention: Chlorhexidine/lidocaine spray
Number of subjects: 154
Study: 18193695

Group type: COMPARATOR
Intervention: Secnidazole tablet (reference)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Secnidazole capsule (test)
Number of subjects: 18
Study: 15867048

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acids supplementation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Active treatment (continuing omega-3 and omega-6 fatty acids)
Number of subjects: 117
Study: 12186120

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AMP-LRC-1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional amphotericin B (c-amp B)
Number of subjects: 34
Study: 9719718

Group type: EXPERIMENTAL
Intervention: Isoflurane/N2O
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Desflurane/N2O
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl/N2O
Number of subjects: 100

Group type: COMPARATOR
Intervention: All anesthetic techniques
Number of subjects: 100
Study: 7867677

Group type: EXPERIMENTAL
Intervention: Desmin 370 (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desmin 370 (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Desmin 370 (100 mg and 200 mg)
Number of subjects: 12
Study: 2768826

Group type: EXPERIMENTAL
Intervention: cromakalim (n = 12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo (n = 6)
Number of subjects: 18
Study: 773589

Group type: EXPERIMENTAL
Intervention: Combination of methyl‐CCNU and imidazole carboxamide (DTIC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 44
Study: 30783954

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (Healthy subjects receiving no-stent or antiplatelet therapy)
Number of subjects: 155
Study: 28150023

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26254154

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 40

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 40
Study: 24579275

Group type: EXPERIMENTAL
Intervention: Fluoride group (FG, biannual application of fluoride varnish)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (CG, no intervention)
Number of subjects: 400
Study: 21469195

Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (PR) 2-24 mg/d
Number of subjects: 350

Group type: COMPARATOR
Intervention: Ropinirole immediate release (IR) 0.75-24 mg/d
Number of subjects: 350
Study: 18342844

Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) system for lung nodule identification
Number of subjects: 39
Study: 16824155

Group type: EXPERIMENTAL
Intervention: Educational-behavioral intervention (IG) including one home visit and three telephone interviews.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Enhanced usual care group (EUCG) receiving usual clinical care.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Educational-behavioral intervention (IG) after three months.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (IG and EUCG) at nine months.
Number of subjects: 18
Study: 14614930

Group type: EXPERIMENTAL
Intervention: Soft shoe condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hard shoe condition
Number of subjects: 40
Study: 10223244

Group type: EXPERIMENTAL
Intervention: Primary tumors
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metastatic tumors
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Matched primary and metastatic tumors
Number of subjects: 25

Group type: COMPARATOR
Intervention: Primary and metastatic tumors
Number of subjects: 25
Study: 7797652

Group type: EXPERIMENTAL
Intervention: Personal construct counseling
Number of subjects: 75

Group type: COMPARATOR
Intervention: Not counseled (Control)
Number of subjects: 75
Study: 2153006

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg orally every 12 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vancomycin/polymyxin (vancomycin 500 mg orally every 8 hours and polymyxin 100 mg orally every 8 hours)
Number of subjects: 62
Study: 391500

Group type: EXPERIMENTAL
Intervention: 0.1 percent amcinonide cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1 percent betamethasone valerate cream
Number of subjects: 0
Study: 31439681

Group type: EXPERIMENTAL
Intervention: Prenatal vitamin D supplementation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control human bronchial epithelial cell line
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-risk CC genotype
Number of subjects: 2
Study: 28034719

Group type: EXPERIMENTAL
Intervention: Gait training with body weight support on a treadmill (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Gait training with body weight support overground (n=14)
Number of subjects: 28
Study: 25086646

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT), 60-minute sessions of CrossFit™, workouts ranging from 5-30 minutes, 3 sessions per week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moderate-Intensity Aerobic and Resistance Training (ART), 50 minutes of moderate aerobic exercise and full-body resistance training on two sessions per week, 3 sessions per week
Number of subjects: 23
Study: 22269279

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (AP) treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19466633

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 440-calorie breakfast
Number of subjects: 18
Study: 17615455

Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation program (4 sessions with inpatients and 4 weeks at home)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Home based pulmonary rehabilitation program (control group)
Number of subjects: 42
Study: 15230337

Group type: EXPERIMENTAL
Intervention: Rabeprazole formulation 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rabeprazole formulation 2
Number of subjects: 20
Study: 12227646

Group type: EXPERIMENTAL
Intervention: DCLHb (10% solution, approximately 1000 mg/kg)
Number of subjects: 24
Study: 9785750

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7631339

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment (air)
Number of subjects: 34
Study: 2649149

Group type: EXPERIMENTAL
Intervention: soluble slow-release artificial tear insert
Number of subjects: 22
Study: 378317

Group type: EXPERIMENTAL
Intervention: Mysteclin syrup (tetracycline hydrochloride and amphotericin) used as a mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31255801

Group type: EXPERIMENTAL
Intervention: mySmartSkin intervention
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 441
Study: 28318448

Group type: EXPERIMENTAL
Intervention: Urinary incontinence (53 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Psychological resilience (PR)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No urinary incontinence (91 patients)
Number of subjects: 144
Study: 25877360

Group type: EXPERIMENTAL
Intervention: LF rTMS and VR training
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sham rTMS and VR training
Number of subjects: 112
Study: 23148243

Group type: EXPERIMENTAL
Intervention: Glycerol (7%, 14%, and 21% dietary DM)
Number of subjects: 72
Study: 21864626

Group type: EXPERIMENTAL
Intervention: 1mg intradermally (id) HIV‐DNA vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.8mg intramuscularly (im) HIV‐DNA vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant MVA (10^8 pfu)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HIV‐DNA vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBMC assay
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19707015

Group type: EXPERIMENTAL
Intervention: Atorvastatin (statin group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet (diet group)
Number of subjects: 40
Study: 17763935

Group type: EXPERIMENTAL
Intervention: therapy to normalize homocysteine plasma level
Number of subjects: 48

Group type: COMPARATOR
Intervention: no therapy to normalize homocysteine plasma level
Number of subjects: 48
Study: 16445556

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8-24 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methadone (40-100 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 12563623

Group type: EXPERIMENTAL
Intervention: Sorbifer Durules (1 tablet/d) for 4 weeks
Number of subjects: 24
Study: 10522149

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract with arginine and magnesium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional hemorheology
Number of subjects: 20
Study: 8901659

Group type: EXPERIMENTAL
Intervention: Moderate oral anticoagulation (INR 2.0 to 3.0)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard oral anticoagulation (INR 3.0 to 4.5)
Number of subjects: 380
Study: 1930006

Group type: EXPERIMENTAL
Intervention: Ioxaglate 320
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Iopamidol 300
Number of subjects: 300
Study: 6176321

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy plus six courses of MOPP chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three or four courses of MOPP before radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (MOPP-bleomycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOP-BAP (MOPP-bleomycin plus doxorubicin)
Number of subjects: 0
Study: 31812755

Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) prior to primary percutaneous coronary intervention (pPCI)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR)
Number of subjects: 683
Study: 31394603

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 143

Group type: COMPARATOR
Intervention: COBRIT composite scoring
Number of subjects: 143
Study: 28118369

Group type: EXPERIMENTAL
Intervention: Duchenne Muscular Dystrophy (DMD) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy Typical Development (TD) control group
Number of subjects: 45
Study: 26314308

Group type: EXPERIMENTAL
Intervention: Low-osmolarity oral rehydration solution (ORS) (osmolarity: 245, sodium: 75) with added potassium (20 mmol/l)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Modified ReSoMal (osmolarity: 300, sodium: 45)
Number of subjects: 110
Study: 23364255

Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg 2-4 hours before PCI)
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 21371128

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.04% or 0.1%
Number of subjects: 25
Study: 20469685

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 10 mg/kg body weight once at night for 3 months
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 450
Study: 17869300

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 40
Study: 15164114

Group type: EXPERIMENTAL
Intervention: 10,000 IU vitamin A supplementation (VA group; n=970)
Number of subjects: 3636

Group type: EXPERIMENTAL
Intervention: 60 mg iron supplementation (Fe group; n=978)
Number of subjects: 3636

Group type: EXPERIMENTAL
Intervention: Combined supplementation of 10,000 IU vitamin A and 60 mg iron (VAFe group; n=1042)
Number of subjects: 3636

Group type: COMPARATOR
Intervention: Control group (n=626)
Number of subjects: 3636
Study: 11529465

Group type: EXPERIMENTAL
Intervention: Up-front SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Salvage SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Number of subjects: 55
Study: 9476088

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 7515507

Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg/day for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute dexamethasone administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic corticosterone administration
Number of subjects: 0
Study: 3652932

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring program for theophylline
Number of subjects: 169

Group type: COMPARATOR
Intervention: Withdrawal of the therapeutic drug monitoring program
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Reinstatement of the therapeutic drug monitoring program
Number of subjects: 169
Study: 31904295

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Treatment as Usual (TAU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 94
Study: 31046423

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 11955

Group type: COMPARATOR
Intervention: Dabigatran (high-dose)
Number of subjects: 11955

Group type: COMPARATOR
Intervention: Dabigatran (low-dose)
Number of subjects: 11955
Study: 27893033

Group type: EXPERIMENTAL
Intervention: Decision aid for OA of the knee (40-minute video describing risks and benefits of TKR surgery)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Decision aid for OA of the knee
Number of subjects: 336
Study: 26152434

Group type: EXPERIMENTAL
Intervention: Gabby (conversational agent system)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (received a letter indicating health risks)
Number of subjects: 100
Study: 23478546

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal jugular vein access
Number of subjects: 150

Group type: COMPARATOR
Intervention: Landmark-guided subclavian/internal jugular vein access
Number of subjects: 150
Study: 20534818

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg) administered with a standard high-fat meal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Edoxaban (60 mg) administered in a fasted state
Number of subjects: 32
Study: 19671472

Group type: EXPERIMENTAL
Intervention: Cocoa powder (20 g/day) with 250 mL of skimmed milk
Number of subjects: 42

Group type: COMPARATOR
Intervention: Skimmed milk (500 mL/day)
Number of subjects: 42
Study: 17273659

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg/day (N = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Metformin, 1.7 g/day (N = 21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 41
Study: 14742393

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-shot spinal (SSS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) (no-catheter)
Number of subjects: 60
Study: 12392340

Group type: EXPERIMENTAL
Intervention: Action Research Arm (ARA) test
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 15-item scale from ARA test
Number of subjects: 63
Study: 10215947

Group type: EXPERIMENTAL
Intervention: Qualitative serum HCV PCR
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: HCV RNA titres
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Liver histology assessed using modified histological activity index (HAI)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Qualitative HCV PCR in liver biopsies
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Serum HCV quantification
Number of subjects: 132
Study: 8555780

Group type: EXPERIMENTAL
Intervention: Automated blood grouping by gel technology (ID-Sampler II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine microtitre plate and gel techniques
Number of subjects: 0
Study: 2925055

Group type: EXPERIMENTAL
Intervention: 20 mg Is‐5‐Mn
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 40 mg Is‐5‐Mn
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 655957

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Surgery for radiation failures
Number of subjects: 82

Group type: COMPARATOR
Intervention: Preoperative radiation
Number of subjects: 82
Study: 29696401

Group type: EXPERIMENTAL
Intervention: Highest adherence to the Mediterranean diet (3rd tertile) and highest total leisure-time physical activity (3rd tertile)
Number of subjects: 7356

Group type: EXPERIMENTAL
Intervention: Total, light, and moderate-to-vigorous leisure-time physical activity
Number of subjects: 7356
Study: 27643690

Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 300 mg/day for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (one capsule/day for 16 weeks)
Number of subjects: 50
Study: 25824795

Group type: EXPERIMENTAL
Intervention: Educational intervention (conducted by public health midwives)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 520
Study: 22893557

Group type: EXPERIMENTAL
Intervention: 3 mL/kg calfactant by LMA (experimental)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continued on nCPAP (control)
Number of subjects: 26
Study: 20687194

Group type: EXPERIMENTAL
Intervention: Narrative therapy (NT) plus escitalopram
Number of subjects: 72

Group type: COMPARATOR
Intervention: Escitalopram plus usual care
Number of subjects: 72
Study: 19136489

Group type: EXPERIMENTAL
Intervention: RV apex (RVA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: RV high septum (RVHS)
Number of subjects: 73
Study: 17923538

Group type: EXPERIMENTAL
Intervention: Follow-up of fellow eyes at risk for choroidal neovascularization (CNV)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Characteristics of incident lesions
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Visual acuity at the time of incidence
Number of subjects: 364
Study: 15516378

Group type: EXPERIMENTAL
Intervention: Focused ultrasound therapy
Number of subjects: 76